Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibronectin leucine-rich transmembrane protein 2 (FLRT2) is a single-pass type I transmembrane protein that is part of the FLRT family. It contains an extracellular region with an N-terminal leucine-rich repeat domain and a type 3 fibronectin domain, a transmembrane region, and a short cytoplasmic tail. FLRT2 is primarily recognized for its roles in cell adhesion, cell migration, and axon guidance. It participates in both homophilic adhesion (FLRT2-FLRT2) and heterophilic interactions, especially with members of the UNC5 receptor family (notably UNC5B, UNC5D), and other proteins such as FGFR2 and LPHN2. Through these interactions, FLRT2 regulates signaling cascades essential for neural and vascular development, and has a recently described key function in promoting the differentiation of monocytes into macrophages by activating the Akt/mTOR pathway. FLRT2 is also implicated in osteoclast maturation and various human cancers, with context-dependent roles that can either suppress or promote tumor cell migration and adhesion. Aberrant epigenetic regulation of FLRT2 (e.g., promoter hypermethylation) has been linked with prostate, breast, and colorectal cancer. FLRT2 is broadly expressed in brain, heart, skeletal muscle, and certain immune cells, and its functions suggest potential as a disease biomarker and therapeutic target in immune, neurodevelopmental, and cancer contexts
Modulation of FLRT2 interacts with UNC5B to activate Akt/mTOR pathway (for differentiation); Epigenetic regulation (e.g., methylation patterns in cancer); Potential regulation via receptor activator of nuclear factor-κB ligand (RANKL) signaling in osteoclasts
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibronectin leucine-rich transmembrane protein 2 (FLRT2).